480 Evidence from the phase III AVADO study reveals no increase in tumour malignant potential following treatment of metastatic breast cancer (mBC) with bevacizumab (BV) and docetaxel (D)

✍ Scribed by A. Chan; D.W. Miles; D. ten Bokkel Huinink; X. Durando; C. Fabiani; S. Salvagni; L. Pérez-Michel; A. Schneeweiss; N. Harbeck

• Book ID: 119601486
• Publisher: Elsevier Science
• Year: 2010
• Tongue: English
• Weight: 65 KB
• Volume: 8
• Category: Article
• ISSN: 1359-6349
• DOI: 10.1016/s1359-6349(10)70501-2